NY-CARESTREAM-HEALTH
20.2.2024 21:42:30 CET | Business Wire | Press release
Carestream Health will exhibit its expanding portfolio of innovative, industry-leading medical imaging solutions at the annual European Congress of Radiology (ECR) from 28th February to 3rd March in Vienna Building on its century-long foundation of imaging research science, the company will showcase its diagnostic imaging solutions that help improve clinical outcomes, enhance the imaging experience for users and patients, and strengthen the financial position of healthcare facilities.
“We understand that the radiology industry across the world is facing challenges such as a shortage of skilled staff and consequently radiologists are dealing with increased workload demands,” said Jane Moverley, International Sales Director, Digital Radiology. “This is why Carestream solutions add significant value to the imaging process. For example, our new DRX-LC Detector helps deliver high-quality, long-length imaging with a single exposure to deliver a more user-friendly workflow, optimize productivity, and ease the physical stress on radiographers. We are also showcasing our expanding line of X-ray solutions that deliver high-quality imaging to meet our customers’ needs at an affordable price.”
Solutions to Help Improve Clinical Outcomes
DRX-Compass X-ray System
- Exceptional image quality
- Scalable and upgradeable technology
- Available in floor-mount or OTC configuration
DRX-Revolution Mobile X-ray System
- Our original X-ray Room on Wheels offering provides superb image quality, maneuverability, and on-board storage.
- Robust functionality with Carestream’s most advanced image processing is available in a single platform.
- Low-profile design and flexibility mean you can easily capture images wherever you need them most.
Solutions to Enhance User and Patient Experience
DRX-LC Detector
- Captures long-length images with a single exposure
- Saves exam time and speeds up workflow
- Decreases retakes
- Allows a higher level of patient comfort
ImageView Software
- Provides high-image quality with AI and advanced image processing technology
- Delivers a quick and sleek operator experience via a single-screen workflow
- Allows users to track analytics on key parameters such as exposure rates and number of rejections
- Provides dose reporting
Solutions to Strengthen Financial Position
New DRX-Rise Mobile X-ray System
- Cutting-edge features in a fully-integrated, digital X-ray unit provide an affordable path to digital imaging.
- Efficiency-boosting features include two touchscreen displays, a state-of-the-art lithium battery, and in-bin detector charging.
- Bedside imaging minimizes disruption and helps deliver an improved patient experience.
DR Detectors
- These are the right detector for every facility, workflow, and budget.
- X-Factor capability lets you share detectors across your facility.
- Upgrade your existing film or CR systems to full wireless DR with a retrofit system and detector.
- Various cassette sizes let you choose the best fit.
Full Suite of Imaging Solutions on Display at ECR 2024
Carestream will also display additional imaging innovations at Expo X2-Booth 220 at ECR. These will include the DRX-Compass X-ray System, DRX-Rise Mobile X-ray System, and DRX-Revolution Mobile X-ray System, as well as our suite of DR Detectors.
Schedule an appointment to discuss Carestream’s latest innovations and other medical imaging solutions at ECR 2024.
About Carestream Health
Carestream is a worldwide provider of medical imaging systems; X-ray imaging systems for non-destructive testing; and precision contract coating services for a wide range of industrial, medical, electronic, and other applications—all backed by a global service and support network. For more information about the company’s broad portfolio of products, solutions, and services, please contact your Carestream representative, or call 1-888-777-2072, or visit www.carestream.com.
CARESTREAM is a trademark of Carestream Health.
“Rx only”
2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220770604/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom